Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs

Therapeutic Drug Monitoring

Volumn 38, Issue 2, 2016, Pages S57-S69

  Picard, Nicolas ^a   Bergan, Stein ^b   Marquet, Pierre ^a   Van Gelder, Teun ^c   Wallemacq, Pierre ^d,e   Hesselink, Dennis A ^c   Haufroid, Vincent ^d,e  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF OSLO   (Norway)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Calcineurin inhibitor; MTORi; Mycophenolic acid; Pharmacogenetics; Polymorphisms

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A9; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TACROLIMUS; CYTOCHROME P450 3A;

CLINICAL OUTCOME; CYP3A5 GENE; DRUG MONITORING; ENZYME POLYMORPHISM; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; NEXT GENERATION SEQUENCING; PHARMACODYNAMIC PARAMETERS; PHARMACOGENETICS; PHARMACOKINETIC PARAMETERS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REVIEW; GENETICS; GRAFT REJECTION; METABOLISM; PROCEDURES;

BIOMARKERS; CYTOCHROME P-450 CYP3A; DRUG MONITORING; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHARMACOGENETICS;

EID: 84944342605     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000255     Document Type: Review

References (148)

1. Kho M, Cransberg K, Weimar W, et al. Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother. 2011;12:1217-1231.
2. Hesselink DA, Bouamar R, van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit. 2010; 32:387-393.
3. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 2005;51: 1374-1381.
4. Dai Y, Iwanaga K, Lin YS, et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol. 2004;68:1889-1902.
5. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254.
6. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-todose ratio in renal transplant recipients. Transplantation. 2003;76: 1233-1235.
7. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147-154.
8. Haufroid V, Wallemacq P, Van Kerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant. 2006;6:2706-2713.
9. Asberg A, Midtvedt K, van Guilder M, et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int. 2013;26:1198-1207.
10. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010; 87:721-726.
11. de Jonge H, de Loor H, Verbeke K, et al. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92:366-375.
12. Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274-286.
13. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57:1574-1583.
14. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011;12:1383-1396.
15. Elens L, Capron A, van Schaik RH, et al. Impact of CYP3A4∗22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35:608-616.
16. Zhu HJ, Yuan SH, Fang Y, et al. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J. 2011;11:237-246.
17. Tang HL, Ma LL, Xie HG, et al. Effects of the CYP3A5∗3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis. Pharmacogenet Genomics. 2010;20:525-531.
18. Moes DJ, Swen JJ, den Hartigh J, et al. Effect of CYP3A4∗22, CYP3A5∗ 3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT Pharmacometrics Syst Pharmacol. 2014;3:e100.
19. Lunde I, Bremer S, Midtvedt K, et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol. 2014;70:685-693.
20. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimustreated renal transplant recipients. Pharmacogenet Genomics. 2008;18: 339-348.
21. Satoh S, Saito M, Inoue T, et al. CYP3A5∗1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2009;65:473-481.
22. Bouamar R, Hesselink DA, van Schaik RH, et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit. 2011;33:178-184.
23. Glowacki F, Lionet A, Buob D, et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant. 2011;26:3046-3050.
24. Terrazzino S, Quaglia M, Stratta P, et al. The effect of CYP3A5 6986A.G and ABCB1 3435C.T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet Genomics. 2012;22: 642-645.
25. Quteineh L, Verstuyft C, Furlan V, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol. 2008;103: 546-552.
26. Min SI, Kim SY, Ahn SH, et al. CYP3A5∗1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation. 2010;90:1394-1400.
27. Tang HL, Xie HG, Yao Y, et al. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics. 2011;21:713-720.
28. Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5∗3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15:38-48.
29. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther. 2007;82:711-725.
30. Kuypers DR, Naesens M, de Jonge H, et al. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit. 2010;32:394-404.
31. Kuypers DR, de Jonge H, Naesens M, et al. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther. 2010;32:2012-2023.
32. Shi Y, Li Y, Tang J, et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 2013;512: 226-231.
33. Kreutz R, Bolbrinker J, van der Sman-de Beer F, et al. CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J. 2008;8:416-422.
34. Kreutz R, Zurcher H, Kain S, et al. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics. 2004;14: 665-671.
35. Elens L, Bouamar R, Hesselink DA, et al. The new CYP3A4 intron 6 C.T polymorphism (CYP3A4∗22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporinetreated kidney transplant patients. Pharmacogenet Genomics. 2012; 22:373-380.
36. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-6080.
37. Hebert MF. Contributions of hepatic and intestinal metabolism and Pglycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997;27:201-214.
38. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169-174.
39. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43: 285-307.
40. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
41. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-3478.
42. Bodor M, Kelly EJ, Ho RJ. Characterization of the human MDR1 gene. AAPS J. 2005;7:E1-E5.
43. Shi XJ, Geng F, Jiao Z, et al. Association of ABCB1, CYP3A4∗18B and CYP3A5∗3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J Clin Pharm Ther. 2011;36:614-624.
44. Yoon SH, Cho JH, Kwon O, et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). Transplantation. 2013;95: 828-834.
45. Gomez-Bravo MA, Salcedo M, Fondevila C, et al. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. J Clin Pharmacol. 2013;53:1146-1154.
46. Kurzawski M, Dabrowska J, Dziewanowski K, et al. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus doseadjusted trough concentrations in kidney transplant recipients. Pharmacogenomics. 2014;15:179-188.
47. Singh R, Srivastava A, Kapoor R, et al. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period? J Clin Pharmacol. 2011;51:603-615.
48. Li Y, Hu X, Cai B, et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transpl Immunol. 2012;27:12-18.
49. Liu YY, Li C, Cui Z, et al. The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis. Gene. 2013;531:476-488.
50. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315: 525-528.
51. Metalidis C, Lerut E, Naesens M, et al. Expression of CYP3A5 and Pglycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Transplantation. 2011;91:1098-1102.
52. Crettol S, Venetz JP, Fontana M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008;18:307-315.
53. Capron A, Mourad M, De Meyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11:703-714.
54. Dessilly G, Elens L, Panin N, et al. ABCB1 1199G.A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One. 2014; 9:e91555.
55. Bandur S, Petrasek J, Hribova P, et al. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation. 2008;86:1206-1213.
56. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47:1048-1052.
57. Cattaneo D, Ruggenenti P, Baldelli S, et al. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol. 2009;20:1404-1415.
58. Gervasini G, Garcia M, Macias RM, et al. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int. 2012;25:471-480.
59. Taegtmeyer AB, Breen JB, Smith J, et al. ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. Transplantation. 2010;89:75-82.
60. Falck P, Asberg A, Guldseth H, et al. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation. 2008;85:179-184.
61. Capron A, Lerut J, Latinne D, et al. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int. 2012;25:41-47.
62. Vafadari R, Bouamar R, Hesselink DA, et al. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther Drug Monit. 2013;35:459-465.
63. Gijsen VM, Madadi P, Dube MP, et al. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant. 2012;17: 111-121.
64. Garcia M, Macias RM, Cubero JJ, et al. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol. 2013; 69:385-393.
65. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol. 2005;16: 1501-1511.
66. Woillard JB, Rerolle JP, Picard N, et al. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term followup. Clin Pharmacol Ther. 2010;88:95-100.
67. Naesens M, Lerut E, de Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol. 2009;20:2468-2480.
68. Tavira B, Gomez J, Diaz-Corte C, et al. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. J Hum Genet. 2015;60:273-276.
69. Oneda B, Crettol S, Jaquenoud Sirot E, et al. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics. 2009;19:877-883.
70. Gijsen VM, van Schaik RH, Soldin OP, et al. P450 oxidoreductase ∗28 (POR∗28) and tacrolimus disposition in pediatric kidney transplant recipients-a pilot study. Ther Drug Monit. 2014;36:152-158.
71. de Jonge H, Metalidis C, Naesens M, et al. The P450 oxidoreductase ∗28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011;12:1281-1291.
72. Zhang JJ, Zhang H, Ding XL, et al. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur J Clin Pharmacol. 2013;69:807-812.
73. Kurzawski M, Malinowski D, Dziewanowski K, et al. Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients. Pharmacogenet Genomics. 2014;24:397-400.
74. Lesche D, Sigurdardottir V, Setoud R, et al. CYP3A5∗3 and POR∗28 genetic variants influence the required dose of tacrolimus in heart transplant recipients. Ther Drug Monit. 2014;36:710-715.
75. Elens L, Hesselink DA, Bouamar R, et al. Impact of POR∗28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther Drug Monit. 2014;36:71-79.
76. Elens L, Sombogaard F, Hesselink DA, et al. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-alpha are associated with the development of newonset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenet Genomics. 2013;23:649-657.
77. Klein K, Thomas M, Winter S, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 2012;91: 1044-1052.
78. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98:19-24.
79. van Gelder T, van Schaik RH, Hesselink DA. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol. 2014;10:725-731.
80. van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int. 2015;28:508-515.
81. Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004;5:1333-1345.
82. Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics. 2010;11:369-390.
83. Kuypers DR, Naesens M, Vermeire S, et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78:351-361.
84. Dupuis R, Yuen A, Innocenti F. The influence of UGT polymorphisms as biomarkers in solid organ transplantation. Clin Chim Acta. 2012;413: 1318-1325.
85. Picard N, Yee SW, Woillard JB, et al. The role of organic aniontransporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther. 2010;87:100-108.
86. van Schaik RH, van Agteren M, de Fijter JW, et al. UGT1A9-275T.A/-2152C.T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009;86:319-327.
87. Johnson LA, Oetting WS, Basu S, et al. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur J Clin Pharmacol. 2008;64:1047-1056.
88. Levesque E, Delage R, Benoit-Biancamano MO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther. 2007;81:392-400.
89. Pazik J, Oldak M, Dabrowski M, et al. Association of UDPglucuronosyltransferase 1A9 (UGT1A9) gene polymorphism with kidney allograft function. Ann Transplant. 2011;16:69-73.
90. Michelon H, Konig J, Durrbach A, et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010;11:1703-1713.
91. Woillard JB, Picard N, Thierry A, et al; DOMINOS Study Group. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics. 2014;24: 256-262.
92. Woillard JB, Rerolle JP, Picard N, et al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br J Clin Pharmacol. 2010;69:675-683.
93. van Agteren M, Armstrong VW, van Schaik RH, et al. Acyl MPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G. A gene polymorphism. Ther Drug Monit. 2008;30: 439-444.
94. Prausa SE, Fukuda T, Maseck D, et al. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;85: 495-500.
95. Jacobson PA, Schladt D, Oetting WS, et al. Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation. 2011;91:309-316.
96. Bouamar R, Elens L, Shuker N, et al. Mycophenolic acid-related anemia and leucopenia in renal transplant recipients are related to genetic polymorphisms in CYP2C8. Transplantation. 2012;93:e39-e40; author reply e1-e2.
97. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistanceassociated protein 2. Am J Transplant. 2005;5:987-994.
98. Naesens M, Kuypers DR, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006;82:1074-1084.
99. Lloberas N, Torras J, Cruzado JM, et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. Nephrol Dial Transplant. 2011;26:3784-3793.
100. Wang J, Figurski M, Shaw LM, et al. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transpl Immunol. 2008;19: 192-196.
101. Bouamar R, Hesselink DA, van Schaik RH, et al. Mycophenolic acidrelated diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenet Genomics. 2012;22:399-407.
102. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2007;8:787-802.
103. Hamada A, Sissung T, Price DK, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008;14: 3312-3318.
104. Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007; 63:1161-1169.
105. Miura M, Kagaya H, Satoh S, et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008;30:559-564.
106. Burckart GJ, Figg WD II, Brooks MM, et al. Multi-institutional study of outcomes after pediatric heart transplantation: candidate gene polymorphism analysis of ABCC2. J Pediatr Pharmacol Ther. 2014;19:16-24.
107. Natsumeda Y, Ohno S, Kawasaki H, et al. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990;265:5292-5295.
108. Wu TY, Peng Y, Pelleymounter LL, et al. Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics. Br J Pharmacol. 2010;161:1584-1598.
109. Gensburger O, Van Schaik RH, Picard N, et al. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics. 2010;20:537-543.
110. Sanquer S, Maison P, Tomkiewicz C, et al. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther. 2008;83:328-335.
111. Bremer S, Vethe NT, Rootwelt H, et al. Expression of IMPDH1 is regulated in response to mycophenolate concentration. Int Immunopharmacol. 2009;9:173-180.
112. Shah S, Harwood SM, Dohler B, et al. Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome. Transplantation. 2012;94:486-491.
113. Sombogaard F, van Schaik RH, Mathot RA, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T. C polymorphism. Pharmacogenet Genomics. 2009;19:626-634.
114. Wang J, Zeevi A, Webber S, et al. A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics. 2007;17:283-290.
115. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther. 2008;83:711-717.
116. Grinyo J, Vanrenterghem Y, Nashan B, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int. 2008;21:879-891.
117. Kagaya H, Miura M, Saito M, et al. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. Basic Clin Pharmacol Toxicol. 2010;107:631-636.
118. Ohmann EL, Burckart GJ, Brooks MM, et al. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant. 2010;29:509-516.
119. Daher Abdi Z, Premaud A, Essig M, et al. Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. Clin Pharmacol Ther. 2014;96:508-515.
120. Gourishankar S, Houde I, Keown PA, et al. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol. 2010;5:1282-1289.
121. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000;356:194-202.
122. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation. 2005;80:244-252.
123. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006;6:514-522.
124. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002;74:1070-1076.
125. Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015;20:1243-1249.
126. Ganschow R, Pollok JM, Jankofsky M, et al. The role of everolimus in liver transplantation. Clin Exp Gastroenterol. 2014;7:329-343.
127. Lampen A, Zhang Y, Hackbarth I, et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther. 1998;285:1104-1112.
128. Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc. 2001;33:514-515.
129. Picard N, Djebli N, Sauvage FL, et al. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos. 2007;35:350-355.
130. Picard N, Rouguieg-Malki K, Kamar N, et al. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation. 2011;91: 652-656.
131. Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation. 2005;80:977-984.
132. Zochowska D, Wyzgal J, Paczek L. Impact of CYP3A4∗1B and CYP3A5∗ 3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Ann Transplant. 2012;17: 36-44.
133. Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant. 2005;5:595-603.
134. Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5∗3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther. 2006;80:51-60.
135. Miao LY, Huang CR, Hou JQ, et al. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos. 2008;29:1-5.
136. Lee J, Huang H, Chen Y, et al. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos. 2014;35:164-172.
137. Woillard JB, Kamar N, Coste S, et al. Effect of CYP3A4∗22, POR∗28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients. Clin Chem. 2013;59: 1761-1769.
138. Elens L, Nieuweboer AJ, Clarke SJ, et al. Impact of POR∗28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet Genomics. 2013;23:148-155.
139. Lemaitre F, Bezian E, Goldwirt L, et al. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. Ther Drug Monit. 2012;34:686-694.
140. Schoeppler KE, Aquilante CL, Kiser TH, et al. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant. 2014;28:590-597.
141. Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin Transplant. 2011;25:146-150.
142. Moes DJ, Press RR, den Hartigh J, et al. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012;51:467-480.
143. Bandur S, Petrasek J, Hribova P, et al. Haplotypic arrangement in CYP3A locus is associated with side effects of proliferative signal inhibitors in renal transplant recipients. Transplantation. 2011;91: e1-2.
144. Lamoureux F, Picard N, Boussera B, et al. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. Fundam Clin Pharmacol. 2012;26:463-472.
145. Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res. 1998;15: 1666-1672.
146. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther. 2003;2:222-232.
147. Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007;71:771-777.
148. Woillard JB, Kamar N, Rousseau A, et al. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenet Genomics. 2012;22: 725-732.